Received Mar 3, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | 3 | — | — |
No adverse event; ROTATEQ , VAXELIS(PFS) VAXNEUVANCE, VAQTA were administered on 1/5/2026. T/E date was 1/5/2026.; This non-serious spontaneous Safety Report was received with reference number: 02928063 (Interaction number: 02928042) by partner on 06-JAN-2026 and forwarded to agency on 06-JAN-2026. NON-SIGNIFICANT FOLLOW-UP INFORMATION was received from Partner on 06-JAN-2026 and forwarded to agency on 07-JAN-2026 from a from a Health professional. Due to the nature of the events, the causality between the event ROTATEQ, VAXELIS(PFS) VAXNEUVANCE, VAQTA were administered on 1/5/2026. T/E date was 1/5/2026' are not applicable. This case is considered nonvalid due to no patient identifiers provided. Further information expected. SIGNIFICANT FOLLOW-UP INFORMATION was received on 19-JAN-2026 from a Health professional. The case is now valid. Due to the nature of the event, the causality between the event ROTATEQ, VAXELIS(PFS) VAXNEUVANCE, VAQTA were administered on 1/5/2026. T/E date was 1/5/2026' is not applicable. No further information is expected.
Prophylaxis